ANXA1 and KRT17 consistently demonstrated expression trends that concurred with our overall bioinformatics analysis in six out of seven pancreatic cancer patients, indicating heightened expression in tumor tissues. This evidence concerns the gene ANXA1 and pancreatic neoplasm.